Suppressed clinical experimental autoimmune myasthenia gravis in bm12 mice is linked to reduced intracellular calcium mobilization and IL-10 and IFN-γ release by acetylcholine receptor-specific T cells

Journal of Neuroimmunology

Volumn 134, Issue 1-2, 2003, Pages 104-110

  Poussin, Mathilde A ^a   Fuller, Claudette L ^b   Goluszko, Elzbieta ^c   Reyes, Victor E ^c   Braciale, Vivian L ^c   Christadoss, Premkumar ^c  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Antigen presentation; Autoimmunity; Class II MHC; Cytokines; Mouse model; Myasthenia gravis

Indexed keywords

CALCIUM; CHOLINERGIC RECEPTOR; CYTOKINE; EPITOPE; GAMMA INTERFERON; INTERLEUKIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CELL SPECIFICITY; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE RELEASE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; INCIDENCE; MOUSE; MOUSE MUTANT; MOUSE STRAIN; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; CALCIUM; CALCIUM SIGNALING; DOWN-REGULATION; EPITOPES; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNE TOLERANCE; IMMUNITY, NATURAL; INTERFERON TYPE II; INTERLEUKIN-10; INTRACELLULAR FLUID; MICE; MICE, INBRED C57BL; MUTATION; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; PEPTIDE FRAGMENTS; RECEPTORS, CHOLINERGIC; SIGNAL TRANSDUCTION; SPLEEN; T-LYMPHOCYTES;

EID: 0037222961     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(02)00425-3     Document Type: Article

References (36)

1. Balasa B., Deng C., Lee J., Bradley L.M., Dalton D.K., Christadoss P., Sarvetnick N. Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. J. Exp. Med. 186:1997;385-391.
2. Bell J., Rassenti L., Smoot S., Smith K., Newby C., Hohlfeld R., Toyka K., McDevitt H., Steinman L. HLA-DQ beta-chain polymorphism linked to myasthenia gravis. Lancet. 1:1986;1058-1060.
3. Bellone M., Ostlie N., Lei S., Conti-Tronconi B.M. Experimental myasthenia gravis in congenic mice. Sequence mapping and H-2 restriction of T helper epitopes on the alpha subunits of Torpedo californica and murine acetylcholine receptors. Eur. J. Immunol. 21:1991;2303-2310.
4. + cells sensitized to nicotinic acetylcholine receptor. J. Immunol. 147:1991;1484-1491.
5. + T cells into Th1 and Th2 subsets. J. Immunol. 159:1997;5802-5809.
6. Chiang B.L., Bearer E., Ansari A., Dorshkind K., Gershwin M.E. The BM12 mutation and autoantibodies to dsDNA in NZB.H-2bm12 mice. J. Immunol. 145:1990;94-101.
7. Christadoss P., Dauphinee M.J. Immunotherapy for myasthenia gravis: a murine model. J. Immunol. 136:1986;2437-2440.
8. Christadoss P., Lennon V.A., Krco C.J., Lambert E.H., David C.S. Genetic control of autoimmunity to acetylcholine receptors: role of I-A molecules. Ann. N.Y. Acad. Sci. 377:1981;258-277.
9. Christadoss P., Lindstrom J.M., Melvold R.W., Talal N. Mutation at I-A beta chain prevents experimental autoimmune myasthenia gravis. Immunogenetics. 21:1985;33-38.
10. Christadoss P., Poussin M., Deng C. Animal models of myasthenia gravis. Clin. Immunol. 94:2000;75-87.
11. Dedhia V., Goluszko E., Wu B., Deng C., Christadoss P. The effect of B cell deficiency on the immune response to acetylcholine receptor and the development of experimental autoimmune myasthenia gravis. Clin. Immunol. Immunopathol. 87:1998;266-275.
12. Drachman D.B., Adams R.N., Stanley E.F., Pestronk A. Mechanisms of acetylcholine receptor loss in myasthenia gravis. J. Neurol. Neurosurg. Psychiatry. 43:1980;601-610.
13. Drachman D.B., McIntosh K.R., Yang B. Factors that determine the severity of experimental myasthenia gravis. Ann. N.Y. Acad. Sci. 13:1998;262-282.
14. Fuchs S., Nevo D., Tarrab-Hazdai R., Yaar I. Strain differences in the autoimmune response of mice to acetylcholine receptors. Nature. 263:1976;329-330.
15. Fujii Y., Lindstrom J. Regulation of antibody production by helper T cell clones in experimental autoimmune myasthenia gravis. J. Immunol. 141:1988;3361-3369.
16. + cytotoxic T lymphocyte effector function by staphylococcus enterotoxin B. J. Immunol. 161:1998;5179-5186.
17. Gur H., Mendel I., Kerlero de Rosbo N., Ben-Nun A. Effect of the bm12 class II mutation on proliferative and cytokine responses of encephalitogenic T cells in myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis. J. Autoimmun. 13:1999;3-10.
18. Infante A.J., Thompson P.A., Krolick K.A., Wall K.A. Determinant selection in murine experimental autoimmune myasthenia gravis. Effect of the bm12 mutation on T cell recognition of acetylcholine receptor epitopes. J. Immunol. 146:1991;2977-2982.
19. Ito S., Ueno M., Nishi S., Arakawa M., Ikarashi Y., Saitoh T., Fujiwara M. Histological characteristics of lupus nephritis in F1 mice with chronic graft-versus-host reaction across MHC class II difference. Autoimmunity. 12:1992;79-87.
20. Kaul R., Shenoy M., Goluszko E., Christadoss P. Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis. J. Immunol. 152:1994;3152-3157.
21. Leitenberg D., Boutin Y., Constant S., Bottomly K. CD4 regulation of TCR signaling and T cell differentiation following stimulation with peptides of different affinities for the TCR. J. Immunol. 161:1998;1194-1203.
22. McIntyre K.R., Seidman J.G. Nucleotide sequence of mutant I-A beta bm12 gene is evidence for genetic exchange between mouse immune response genes. Nature. 308:1984;551-553.
23. McKenzie I.F., Morgan G.M., Sandrin M.S., Michaelides M.M., Melvold R.W., Kohn H.I. B6.C-H-2bm12. A new H-2 mutation in the I region in the mouse. J. Exp. Med. 150:1979;1323-1338.
24. Mozes E., Dayan M., Zisman E., Brocke S., Licht A., Pecht I. Direct binding of a myasthenia gravis related epitope to MHC class II molecules on living murine antigen-presenting cells. EMBO J. 8:1989;4049-4052.
25. Naiki M., Yoshida S.H., Watanabe Y., Izui S., Ansari A.A., Gershwin M.E. The contribution of I-Abm12 to phenotypic and functional alterations among T-cell subsets in NZB mice. J. Autoimmun. 6:1993;131-143.
26. Nicholson L.B., Waldner H., Carrizosa A.M., Sette A., Collins M., Kuchroo V.K. Heteroclitic proliferative responses and changes in cytokine profile induced by altered peptides: implications for autoimmunity. Proc. Natl. Acad. Sci. U. S. A. 95:1998;264-269.
27. Oshima M., Atassi M.Z. Effect of amino acid substitutions within the region 62-76 of I-A beta b on binding with and antigen presentation of Torpedo acetylcholine receptor alpha-chain peptide 146-162. J. Immunol. 154:1995;5245-5254.
28. Poussin M.A., Goluszko E., Hughes T.K., Duchicella S.I., Christadoss P. Suppression of experimental autoimmune myasthenia gravis in IL-10 gene-disrupted mice is associated with reduced B cells and serum cytotoxicity on mouse cell line expressing AChR. J. Neuroimmunol. 111:2000;152-160.
29. Robinson J.H., Delvig A.A. Diversity in MHC class II antigen presentation. Immunology. 105:2002;252-262.
30. Sahashi K., Engel A.G., Linstrom J.M., Lambert E.H., Lennon V.A. Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis. J. Neuropathol. Exp. Neurol. 37:1978;212-223.
31. Shenoy M., Oshima M., Atassi M.Z., Christadoss P. Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance to synthetic region alpha 146-162 of acetylcholine receptor. Clin. Immunol. Immunopathol. 66:1993;230-238.
32. Shenoy M., Goluszko E., Christadoss P. The pathogenic role of acetylcholine receptor alpha chain epitope within alpha 146-162 in the development of experimental autoimmune myasthenia gravis in C57BL6 mice. Clin. Immunol. Immunopathol. 73:1994;338-343.
33. + cells. Neurology. 52:1999;484-497.
34. Wang J.H., Meijers R., Xiong Y., Liu J.H., Sakihama T., Zhang R., Joachimiak A., Reinherz E.L. Crystal structure of the human CD4 N-terminal two-domain fragment complexed to a class II MHC molecule. Proc. Natl. Acad. Sci. U. S. A. 98:2001;10799-10804.
35. Wu B., Goluszko E., Christadoss P. Experimental autoimmune myasthenia gravis in the mouse. Coligan J.E., Kruisbeek A.M., Margulies D.H., Shevach E.M., Strober W. Current Protocols in Immunology. vol. 3:1997;8.1-8.16 Wiley, New York.
36. Yang B., McIntosh K.R., Drachman D.B. How subtle differences in MHC class II affect the severity of experimental myasthenia gravis. Clin. Immunol. Immunopathol. 86:1998;45-58.